Catch up on May’s top pharma news in this monthly round-up. From the latest HCP insights on pharma companies to new investments, there’s plenty to discover.

Neuralink, Elon Musk’s brain chip company, is preparing for the first clinical trial of its implant technology.

The FDA has granted Breakthrough Device Designation to Roche’s new blood test, developed in collaboration with Amgen, that measures key blood markers of inherited cardiovascular risk.

GSK has pledged £45m to the Fleming Initiative, a UK scheme to tackle antimicrobial resistance, led by Imperial College Healthcare NHS Trust and Imperial College London.

Pfizer and AstraZeneca have set their sights on France with major investments totalling nearly 1bn (USD) ahead of the country’s annual ‘Choose France’ business summit.

Catch up on the top stories to come from the pharma industry over April, including new collaborations set to improve treatments for patients, the latest approvals and more.

The pharma industry’s ability to recoup costs on their drug development pipeline was in trouble, been is the downward spiral coming to an end? Read more.

The orphan drug market has seen robust growth over the past decade, but may face challenges in maintaining its trajectory due to evolving investor and payer preferences.